Amelia Bond on 340B's Influence on Biosimilars

Health Affairs Editor-in-Chief Alan Weil interviews Amelia Bond from Weill Cornell Medical College on her paper exploring whether participation in the 340B drug program influences biosimilar uptake. Bond and coauthors found that in hospital outpatient settings, 340B program eligibility is associated with a lower use of biosimilars and more hospital-based administrations of and revenues from biologics. Order the May 2023 issue of Health Affairs.Currently, more than 70 percent of our content is freely available - and we'd like to keep it that way. With your support, we can continue to keep our digital publication Forefront and podcasts free for everyone.Subscribe: RSS | Apple Podcasts | Spotify | Stitcher | Google Podcasts